Panacea Biotec Analyst Review May 2026

This Panacea Biotec analyst review for May 2026 covers all critical data investors need for PANACEABIO at Rs 419.05. Panacea Biotec is a vaccine and pharmaceutical company. This Panacea Biotec analyst review analyses technical levels, business fundamentals, valuation, and key risks for PANACEABIO through FY27.

Click Here – Get Free Investment Predictions

Panacea Biotec Analyst Review: Company Snapshot May 2026

Panacea Biotec produces vaccines including pentavalent, IPV, and rotavirus vaccines for domestic immunisation programmes and global export. The table below summarises key metrics for this Panacea Biotec analyst review.

Parameter	Value
NSE Ticker	PANACEABIO
Sector	Pharmaceuticals – Vaccines
CMP (May 2026)	Rs 419.05
52 Week High	Rs 502.85
52 Week Low	Rs 335.25
Market Cap	Rs 3500 Crore
Trailing P/E	NAx
Analyst Consensus Target	Rs 523.81
Bull Case Target	Rs 649.53
Bear Case Target	Rs 356.19

Analyst Insight: Panacea Biotec Analyst Review for FY27

Associate Director Kunal Singla suggests watching Panacea Biotec closely in May 2026. At Rs 419.05, Kunal Singla flags Pharmaceuticals – Vaccines sector dynamics as the key driver for PANACEABIO’s price action. Support is near Rs 341.95 and resistance near Rs 444.19. Kunal Singla’s perspective in this Panacea Biotec analyst review is not a buy recommendation.

Technical Analysis in This Panacea Biotec Analyst Review

This Panacea Biotec analyst review places PANACEABIO at Rs 419.05 within its 52-week band of Rs 335.25 to Rs 502.85. The 14-day RSI, MACD signal, and volume profile are key technical inputs when evaluating PANACEABIO.

The Panacea Biotec analyst review identifies support in the Rs 341.95 to Rs 398.10 range and resistance in the Rs 444.19 to Rs 471.43 zone. A sustained close above Rs 444.19 could signal momentum toward the analyst consensus target of Rs 523.81.

Screen the best stocks on the Univest Screener.

Support and Resistance in This Panacea Biotec Analyst Review

• Support Zone: Rs 341.95 to Rs 398.10 – this Panacea Biotec analyst review identifies this as a potential accumulation signal for PANACEABIO.
• Resistance Zone: Rs 444.19 to Rs 471.43 – the Panacea Biotec analyst review flags a close above Rs 444.19 as a positive signal for PANACEABIO.
• Consensus Target: Rs 523.81 is the base-case target in this Panacea Biotec analyst review.

Business Segments in This Panacea Biotec Analyst Review

Vaccine Manufacturing (Pentavalent, IPV)

This primary segment drives revenue and margin for Panacea Biotec, supporting the earnings trajectory toward Rs 523.81 in this Panacea Biotec analyst review.

Pharma Formulations

This segment adds meaningful scale to Panacea Biotec’s model and is a key EPS contributor through FY27 as identified in this Panacea Biotec analyst review.

Export Vaccines to UNICEF and WHO Markets

This growth frontier is a potential re-rating catalyst for PANACEABIO and a key element of this Panacea Biotec analyst review.

Valuation: Panacea Biotec Analyst Review Bull Bear Base Case

At Rs 419.05 and P/E of NAx, this Panacea Biotec analyst review sets three scenarios: bull case Rs 649.53, base case Rs 523.81, and bear case Rs 356.19.

Scenario	Target Price	Key Condition
Bull Case	Rs 649.53	Strong FY27 delivery and Pharmaceuticals – Vaccines re-rating
Base Case	Rs 523.81	Moderate growth per analyst consensus in this Panacea Biotec analyst review
Bear Case	Rs 356.19	Earnings miss or macro headwinds for PANACEABIO

FY27 Outlook in This Panacea Biotec Analyst Review

This Panacea Biotec analyst review for FY27 is constructive provided PANACEABIO delivers on earnings expectations. Q1 FY27 results will be the first checkpoint. Investors should monitor Pharmaceuticals – Vaccines indicators, RBI policy, and FII flow trends.

Key Risks in This Panacea Biotec Analyst Review

This Panacea Biotec analyst review identifies four key risks for PANACEABIO: macro slowdown, input cost pressure, FII selling, and Q1 FY27 earnings disappointment.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Conclusion: Panacea Biotec Analyst Review Verdict May 2026

This Panacea Biotec analyst review concludes that PANACEABIO at Rs 419.05 presents a defined risk-reward with consensus target Rs 523.81. The 52-week range of Rs 335.25 to Rs 502.85 provides further context. Use this Panacea Biotec analyst review as a research reference and consult a SEBI-registered advisor before investing in PANACEABIO.

FAQs: Panacea Biotec Analyst Review 2026

What is the analyst target for Panacea Biotec in 2026?

The Panacea Biotec analyst review consensus target is Rs 523.81, bull case Rs 649.53, bear case Rs 356.19.

Is Panacea Biotec a good buy at Rs 419.05?

At Rs 419.05 with PE NAx and target Rs 523.81, this Panacea Biotec analyst review is constructive for 12-month investors. Consult a SEBI-registered advisor before acting on this Panacea Biotec analyst review.

What is the 52-week high and low of Panacea Biotec?

52-week high is Rs 502.85 and 52-week low is Rs 335.25. This Panacea Biotec analyst review contextualises PANACEABIO at Rs 419.05 within this range.

What are the key risks for Panacea Biotec?

Key risks in this Panacea Biotec analyst review: macro slowdown, input cost pressure, FII selling, and competitive pressure in the Pharmaceuticals – Vaccines sector.

Where can I track live data for Panacea Biotec?

Track Panacea Biotec’s live price on the Univest Screener to complement this Panacea Biotec analyst review with real-time data.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.